These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2054 related items for PubMed ID: 11544529

  • 21. Transcriptional activation induced in macrophages by Toll-like receptor (TLR) ligands: from expression profiling to a model of TLR signaling.
    Schmitz F, Mages J, Heit A, Lang R, Wagner H.
    Eur J Immunol; 2004 Oct; 34(10):2863-73. PubMed ID: 15368303
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Toll-like receptor signaling pathways.
    Barton GM, Medzhitov R.
    Science; 2003 Jun 06; 300(5625):1524-5. PubMed ID: 12791976
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments.
    Ahmad-Nejad P, Häcker H, Rutz M, Bauer S, Vabulas RM, Wagner H.
    Eur J Immunol; 2002 Jul 06; 32(7):1958-68. PubMed ID: 12115616
    [Abstract] [Full Text] [Related]

  • 26. Inhibition of interleukin 1 receptor/Toll-like receptor signaling through the alternatively spliced, short form of MyD88 is due to its failure to recruit IRAK-4.
    Burns K, Janssens S, Brissoni B, Olivos N, Beyaert R, Tschopp J.
    J Exp Med; 2003 Jan 20; 197(2):263-8. PubMed ID: 12538665
    [Abstract] [Full Text] [Related]

  • 27. Structural complementarity of Toll/interleukin-1 receptor domains in Toll-like receptors and the adaptors Mal and MyD88.
    Dunne A, Ejdeback M, Ludidi PL, O'Neill LA, Gay NJ.
    J Biol Chem; 2003 Oct 17; 278(42):41443-51. PubMed ID: 12888566
    [Abstract] [Full Text] [Related]

  • 28. Viral inhibitory peptide of TLR4, a peptide derived from vaccinia protein A46, specifically inhibits TLR4 by directly targeting MyD88 adaptor-like and TRIF-related adaptor molecule.
    Lysakova-Devine T, Keogh B, Harrington B, Nagpal K, Halle A, Golenbock DT, Monie T, Bowie AG.
    J Immunol; 2010 Oct 01; 185(7):4261-71. PubMed ID: 20802145
    [Abstract] [Full Text] [Related]

  • 29. Differential regulation of interleukin 1 receptor and Toll-like receptor signaling by MEKK3.
    Huang Q, Yang J, Lin Y, Walker C, Cheng J, Liu ZG, Su B.
    Nat Immunol; 2004 Jan 01; 5(1):98-103. PubMed ID: 14661019
    [Abstract] [Full Text] [Related]

  • 30. Toll-like receptor 3-mediated activation of NF-kappaB and IRF3 diverges at Toll-IL-1 receptor domain-containing adapter inducing IFN-beta.
    Jiang Z, Mak TW, Sen G, Li X.
    Proc Natl Acad Sci U S A; 2004 Mar 09; 101(10):3533-8. PubMed ID: 14982987
    [Abstract] [Full Text] [Related]

  • 31. Distinct pathways of LPS-induced NF-kappa B activation and cytokine production in human myeloid and nonmyeloid cells defined by selective utilization of MyD88 and Mal/TIRAP.
    Andreakos E, Sacre SM, Smith C, Lundberg A, Kiriakidis S, Stonehouse T, Monaco C, Feldmann M, Foxwell BM.
    Blood; 2004 Mar 15; 103(6):2229-37. PubMed ID: 14630816
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Inhibition of Toll-like receptors TLR4 and 7 signaling pathways by SIGIRR: a computational approach.
    Gong J, Wei T, Stark RW, Jamitzky F, Heckl WM, Anders HJ, Lech M, Rössle SC.
    J Struct Biol; 2010 Mar 15; 169(3):323-30. PubMed ID: 20025973
    [Abstract] [Full Text] [Related]

  • 34. Toll and Toll-like proteins: an ancient family of receptors signaling infection.
    Imler JL, Hoffmann JA.
    Rev Immunogenet; 2000 Mar 15; 2(3):294-304. PubMed ID: 11256741
    [Abstract] [Full Text] [Related]

  • 35. Cutting edge: a novel Toll/IL-1 receptor domain-containing adapter that preferentially activates the IFN-beta promoter in the Toll-like receptor signaling.
    Yamamoto M, Sato S, Mori K, Hoshino K, Takeuchi O, Takeda K, Akira S.
    J Immunol; 2002 Dec 15; 169(12):6668-72. PubMed ID: 12471095
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. The Toll-like receptor 2 is recruited to macrophage phagosomes and discriminates between pathogens.
    Underhill DM, Ozinsky A, Hajjar AM, Stevens A, Wilson CB, Bassetti M, Aderem A.
    Nature; 1999 Oct 21; 401(6755):811-5. PubMed ID: 10548109
    [Abstract] [Full Text] [Related]

  • 38. Molecular analysis of the binding mode of Toll/interleukin-1 receptor (TIR) domain proteins during TLR2 signaling.
    Nada M, Ohnishi H, Tochio H, Kato Z, Kimura T, Kubota K, Yamamoto T, Kamatari YO, Tsutsumi N, Shirakawa M, Kondo N.
    Mol Immunol; 2012 Oct 21; 52(3-4):108-16. PubMed ID: 22673208
    [Abstract] [Full Text] [Related]

  • 39. Summary and comparison of the signaling mechanisms of the Toll/interleukin-1 receptor family.
    Martin MU, Wesche H.
    Biochim Biophys Acta; 2002 Nov 11; 1592(3):265-80. PubMed ID: 12421671
    [Abstract] [Full Text] [Related]

  • 40. The hepatitis B e antigen (HBeAg) targets and suppresses activation of the toll-like receptor signaling pathway.
    Lang T, Lo C, Skinner N, Locarnini S, Visvanathan K, Mansell A.
    J Hepatol; 2011 Oct 11; 55(4):762-9. PubMed ID: 21334391
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 103.